{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T12:40:11Z","timestamp":1766407211023,"version":"build-2065373602"},"reference-count":55,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T00:00:00Z","timestamp":1684195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004410","name":"BIDEB 2232 International Fellowship for Outstanding Researchers Program of TUBITAK","doi-asserted-by":"publisher","award":["118C327"],"award-info":[{"award-number":["118C327"]}],"id":[{"id":"10.13039\/501100004410","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Systems"],"abstract":"<jats:p>In this study, we present a novel simulation model and case study to explore the long-term dynamics of early detection of disease, also known as routine population screening. We introduce a realistic and portable modeling framework that can be used for most cases of cancer, including a natural disease history and a realistic yet generic structure that allows keeping track of critical stocks that have been generally overlooked in previous modeling studies. Our model is specific to prostate-specific antigen (PSA) screening for prostate cancer (PCa), including the natural progression of the disease, respective changes in population size and composition, clinical detection, adoption of the PSA screening test by medical professionals, and the dissemination of the screening test. The key outcome measures for the model are selected to show the fundamental tradeoff between the main harms and benefits of screening, with the main harms including (i) overdiagnosis, (ii) unnecessary biopsies, and (iii) false positives. The focus of this study is on building the most reliable and flexible model structure for medical screening and keeping track of its main harms and benefits. We show the importance of some metrics which are not readily measured or considered by existing medical literature and modeling studies. While the model is not primarily designed for making inferences about optimal screening policies or scenarios, we aim to inform modelers and policymakers about potential levers in the system and provide a reliable model structure for medical screening that may complement other modeling studies designed for cancer interventions. Our simulation model can offer a formal means to improve the development and implementation of evidence-based screening, and its future iterations can be employed to design policy recommendations to address important policy areas, such as the increasing pool of cancer survivors or healthcare spending in the U.S.<\/jats:p>","DOI":"10.3390\/systems11050252","type":"journal-article","created":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T01:58:06Z","timestamp":1684288686000},"page":"252","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Dynamics of Medical Screening: A Simulation Model of PSA Screening for Early Detection of Prostate Cancer"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2319-0818","authenticated-orcid":false,"given":"\u00d6zge","family":"Karanfil","sequence":"first","affiliation":[{"name":"College of Administrative Sciences and Economics, Ko\u00e7 University, Istanbul 34450, Turkey"},{"name":"Research Center for Translational Medicine (KUTTAM), Ko\u00e7 University, Istanbul 34450, Turkey"},{"name":"School of Medicine, Ko\u00e7 University, Istanbul 34450, Turkey"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1001\/archinternmed.2012.3319","article-title":"Overdiagnosis of Disease","volume":"172","author":"Hoffman","year":"2012","journal-title":"Arch. Intern. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e234","DOI":"10.1016\/S1470-2045(13)70598-9","article-title":"Addressing overdiagnosis and overtreatment in cancer: A prescription for change","volume":"15","author":"Esserman","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_3","unstructured":"(2018). Global Cancer Facts & Figures, American Cancer Society. [4th ed.]. Available online: https:\/\/www.cancer.org\/research\/cancer-facts-statistics\/global.html."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3322\/canjclin.35.1.36","article-title":"Probabilities of Eventually Developing or Dying of Cancer--United States, 1985","volume":"35","author":"Seidman","year":"1985","journal-title":"CA Cancer J. Clin."},{"key":"ref_5","unstructured":"Altekruse, S.F., Kosary, C.L., Krapcho, M., Neyman, N., Aminou, R., Waldron, W., Ruhl, J., Howlader, N., Tatalovich, Z., and Cho, H. (2023, April 12). SEER Cancer Statistics Review, 1975\u20132007, Available online: http:\/\/seer.cancer.gov\/csr\/1975_2007\/."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1200\/JCO.2017.76.4050","article-title":"Prostate Cancer Screening and the Goldilocks Principle: How Much Is Just Right?","volume":"36","author":"Faiena","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40985-018-0080-0","article-title":"Cancer screening recommendations: An international comparison of high income countries","volume":"39","author":"Ebell","year":"2018","journal-title":"Public Health Rev."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"US Preventive Services Task Force (2018). Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. JAMA, 319, 1901\u20131913.","DOI":"10.1001\/jama.2018.3710"},{"key":"ref_9","unstructured":"SEER (2023, March 03). Cancer of the Prostate\u2014Cancer Stat Facts, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/prost.html."},{"key":"ref_10","unstructured":"Sterman, J.D. (2000). Business Dynamics: Systems Thinking and Modeling for a Complex World, Irwin\/McGraw-Hill."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"452","DOI":"10.2105\/AJPH.2005.062059","article-title":"System Dynamics Modeling for Public Health: Background and Opportunities","volume":"96","author":"Homer","year":"2006","journal-title":"Am. J. Public Health"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2105\/AJPH.2005.066043","article-title":"Learning from Evidence in a Complex World","volume":"96","author":"Sterman","year":"2006","journal-title":"Am. J. Public Health"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0040-1625(87)90011-4","article-title":"A diffusion model with application to evolving medical technologies","volume":"31","author":"Homer","year":"1987","journal-title":"Technol. Forecast. Soc. Change"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.2105\/AJPH.2013.301816","article-title":"Using Simulation to Compare 4 Categories of Intervention for Reducing Cardiovascular Disease Risks","volume":"104","author":"Hirsch","year":"2014","journal-title":"Am. J. Public Health"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2105\/AJPH.2009.174490","article-title":"Analyzing National Health Reform Strategies with a Dynamic Simulation Model","volume":"100","author":"Milstein","year":"2010","journal-title":"Am. J. Public Health"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"E09","DOI":"10.5888\/pcd18.200225","article-title":"Validation of the Prevention Impacts Simulation Model (PRISM)","volume":"18","author":"Yarnoff","year":"2021","journal-title":"Prev. Chronic Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.healthpol.2006.05.021","article-title":"Impact of joined-up HIV harm reduction and multidrug resistant tuberculosis control programmes in Estonia: System dynamics simulation model","volume":"81","author":"Atun","year":"2006","journal-title":"Health Policy"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Burns, W.J., and Slovic, P. (2023, April 12). The Diffusion of Fear: Modeling Community Response to a Terrorist Strike (2006). Available online: https:\/\/ssrn.com\/abstract=912736; http:\/\/dx.doi.org\/10.2139\/ssrn.912736.","DOI":"10.2139\/ssrn.912736"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/sdr.1655","article-title":"Simulation-based estimation of the early spread of COVID-19 in Iran: Actual versus confirmed cases","volume":"36","author":"Ghaffarzadegan","year":"2020","journal-title":"Syst. Dyn. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/sdr.1715","article-title":"Quantifying the COVID-19 endgame: Is a new normal within reach?","volume":"38","author":"Rahmandad","year":"2022","journal-title":"Syst. Dyn. Rev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e2115714119","DOI":"10.1073\/pnas.2115714119","article-title":"Modeling the Evolution of the US Opioid Crisis for National Policy Development","volume":"119","author":"Lim","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/sdr.1646","article-title":"System dynamics modeling in health and medicine: A systematic literature review","volume":"36","author":"Darabi","year":"2020","journal-title":"Syst. Dyn. Rev."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/sdr.1481","article-title":"Reporting guidelines for simulation-based research in social sciences","volume":"28","author":"Rahmandad","year":"2012","journal-title":"Syst. Dyn. Rev."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/sdr.1471","article-title":"Documentation for model transparency","volume":"28","year":"2012","journal-title":"Syst. Dyn. Rev."},{"key":"ref_25","unstructured":"Richmond, B. (2023, April 12). Towards a Structural Theory of Cancer. D-Memos. D-4151. MIT Sloan School of Management, Cambridge, MA, USA, 1990. Available online: https:\/\/systemdynamics.org\/d-memos-4000-4499\/."},{"key":"ref_26","unstructured":"Fett, M.J. (2023, April 12). Developing Simulation Dynamic Models of Breast Cancer Screening; Wellington, New Zealand, 1999. Available online: https:\/\/proceedings.systemdynamics.org\/1999\/PAPERS\/PARA47.PDF."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/jms.8.1.39","article-title":"Computer modelling of the Swedish two county trial of mammographic screening and trade offs between participation and screening interval","volume":"8","author":"Fett","year":"2001","journal-title":"J. Med. Screen."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/(SICI)1099-1727(199923)15:3<293::AID-SDR169>3.0.CO;2-1","article-title":"Using System Dynamics to Help Develop and Implement Policies and Programmes in Health Care in England","volume":"15","author":"Royston","year":"1999","journal-title":"Syst. Dyn. Rev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13012-016-0517-0","article-title":"A System Dynamics Model of Clinical Decision Thresholds for the Detection of Developmental-Behavioral Disorders","volume":"11","author":"Sheldrick","year":"2016","journal-title":"Implement. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.acap.2017.01.016","article-title":"Is a Positive Developmental-Behavioral Screening Score Sufficient to Justify Referral? A Review of Evidence and Theory","volume":"17","author":"Sheldrick","year":"2017","journal-title":"Acad. Pediatr."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/aje\/kwv262","article-title":"A System Dynamics Model of Serum Prostate-Specific Antigen Screening for Prostate Cancer","volume":"183","author":"Palma","year":"2015","journal-title":"Am. J. Epidemiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/sdr.1661","article-title":"\u201cSaving lives or harming the healthy?\u201d Overuse and fluctuations in routine medical screening","volume":"36","author":"Karanfil","year":"2020","journal-title":"Syst. Dyn. Rev."},{"key":"ref_33","unstructured":"Karanfil, \u00d6. (2016). Why Clinical Practice Guidelines Shift over Time: A Dynamic Model with Application to Prostate Cancer Screening. [Ph.D. Thesis, Massachusetts Institute of Technology]. Available online: http:\/\/dspace.mit.edu\/handle\/1721.1\/107531."},{"key":"ref_34","unstructured":"(2023, April 12). United States Department of Health and Human Services (US DHHS), Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS), Compressed Mortality File (CMF) on CDC WONDER Online Database, Available online: https:\/\/wonder.cdc.gov\/mortsql.html."},{"key":"ref_35","unstructured":"(2023, April 12). Life Tables for the United States Social Security Area 1900\u20132100. August 2025, Available online: https:\/\/www.ssa.gov\/oact\/NOTES\/as120\/TOC.html."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0895-4356(94)90029-9","article-title":"A Markov model of the natural history of prostate cancer","volume":"47","author":"Cowen","year":"1994","journal-title":"J. Clin. Epidemiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1097\/00005392-199909010-00032","article-title":"Serial prostate specific antigen screening for prostate cancer: A computer model evaluates competing strategies","volume":"162","author":"Etzioni","year":"1999","journal-title":"J. Urol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1002\/sim.2257","article-title":"A population model of prostate cancer incidence","volume":"25","author":"Tsodikov","year":"2006","journal-title":"Stat. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/biostatistics\/kxq036","article-title":"Calibrating disease progression models using population data: A critical precursor to policy development in cancer control","volume":"11","author":"Gulati","year":"2010","journal-title":"Biostatistics"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1287\/opre.1110.1019","article-title":"OR Forum\u2014A POMDP Approach to Personalize Mammography Screening Decisions","volume":"60","author":"Ayer","year":"2012","journal-title":"Oper. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1002\/ijc.29408","article-title":"The high prevalence of undiagnosed prostate cancer at autopsy: Implications for epidemiology and treatment of prostate cancer in the Prostate-specific Antigen-era","volume":"137","author":"Jahn","year":"2015","journal-title":"Int. J. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1002\/ijc.29538","article-title":"Prevalence of incidental prostate cancer: A systematic review of autopsy studies","volume":"137","author":"Bell","year":"2015","journal-title":"Int. J. Cancer"},{"key":"ref_43","first-page":"3866","article-title":"The Worldwide Epidemiology of Prostate Cancer: Perspectives from Autopsy Studies","volume":"15","author":"Haas","year":"2008","journal-title":"Can. J. Urol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Scardino, P.T., Beck, J.R., and Miles, B.J. (1994). Conservative management of prostate cancer. N. Engl. J. Med., 330.","DOI":"10.1056\/NEJM199406233302517"},{"key":"ref_45","first-page":"125","article-title":"Prostate Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality Results after 13 Years of Follow-up","volume":"104","author":"Andriole","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1002\/cncr.22607","article-title":"Reconstructing PSA testing patterns between black and white men in the US from Medicare claims and the National Health Interview Survey","volume":"109","author":"Mariotto","year":"2007","journal-title":"Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S1470-2045(06)70700-8","article-title":"Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy","volume":"7","author":"Messing","year":"2006","journal-title":"Lancet Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/cncr.20855","article-title":"Survival in prostate carcinoma\u2014Outcomes from a prospective, population-based cohort of 8887 men with up to 15 years of follow-up","volume":"103","author":"Aus","year":"2005","journal-title":"Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1046\/j.1525-1497.2003.21105.x","article-title":"Racial differences in initial treatment for clinically localized prostate cancer","volume":"18","author":"Hoffman","year":"2003","journal-title":"J. Gen. Intern. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/S0022-5347(17)40078-4","article-title":"Clinical Evidence for and Implications of the Multistep Development of Prostate Cancer","volume":"143","author":"Carter","year":"1990","journal-title":"J. Urol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1001\/archinternmed.2010.222","article-title":"The Cautionary Tale of Psa Testing: Comment on \u2018risk Profiles and Treatment Patterns among Men Diagnosed as Having Prostate Cancer and a Prostate-Specific Antigen Level below 4.0 Ng\/mL","volume":"170","author":"Hoffman","year":"2010","journal-title":"Arch. Intern. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/sdr.4260030207","article-title":"14 \u2018Obvious Truths\u2019","volume":"3","author":"Forrester","year":"1987","journal-title":"Syst. Dyn. Rev."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1097\/01.ju.0000152697.25708.71","article-title":"Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial","volume":"173","author":"Pinsky","year":"2005","journal-title":"J. Urol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ygyno.2022.12.004","article-title":"Cervical cancer geographical burden analyzer: An interactive, open-access tool for understanding geographical disease burden in patients with recurrent or metastatic cervical cancer","volume":"169","author":"Castellano","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"ref_55","unstructured":"(2023, April 09). Cancer Progress Report. AACR Cancer Progress Report. Available online: https:\/\/cancerprogressreport.aacr.org\/progress\/."}],"container-title":["Systems"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-8954\/11\/5\/252\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:35:59Z","timestamp":1760124959000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-8954\/11\/5\/252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,16]]},"references-count":55,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["systems11050252"],"URL":"https:\/\/doi.org\/10.3390\/systems11050252","relation":{},"ISSN":["2079-8954"],"issn-type":[{"type":"electronic","value":"2079-8954"}],"subject":[],"published":{"date-parts":[[2023,5,16]]}}}